Viscogliosi Brothers

Viscogliosi Brothers, established in 1999, is a New York-based investment firm specializing in venture capital, private equity, and merchant banking within the orthopedics sector of the healthcare industry. The firm focuses on investing in healthcare devices, supplies, and manufacturing, as well as pharmaceuticals and biotechnology in the life sciences sector.

11 past transactions

Stryker - Spinal Implants Business

Acquisition in 2025
Stryker - Spinal Implants Business is a unit of Stryker.

Companion Spine

Series A in 2023
Companion Spine is a spine care company that specializes in interventional therapies and technologies aimed at addressing back pain effectively and with minimal disruption. The company focuses on providing diagnostic and medical implant products that facilitate the immediate and precise identification of spinal conditions and their underlying causes. By prioritizing patient safety and comfort, Companion Spine enables individuals to manage their pain while maintaining full spinal mobility, ultimately enhancing their quality of life.

Spine BioPharma

Convertible Note in 2023
Spine BioPharma is focused on developing non-surgical therapies aimed at alleviating back pain and restoring functionality without relying on opioids. The company’s lead therapeutic candidate targets degenerative disc disease, offering potential benefits such as pain relief, functional restoration, and the slowing or prevention of disease progression. With a mission to enhance the quality of life for individuals suffering from degenerative spine conditions, Spine BioPharma seeks to deliver clinically proven, safe, and effective treatments that address pain and inflammation. Through its innovative pipeline, the company aims to improve the everyday lives of millions affected by these debilitating conditions.

Spine BioPharma

Series B in 2022
Spine BioPharma is focused on developing non-surgical therapies aimed at alleviating back pain and restoring functionality without relying on opioids. The company’s lead therapeutic candidate targets degenerative disc disease, offering potential benefits such as pain relief, functional restoration, and the slowing or prevention of disease progression. With a mission to enhance the quality of life for individuals suffering from degenerative spine conditions, Spine BioPharma seeks to deliver clinically proven, safe, and effective treatments that address pain and inflammation. Through its innovative pipeline, the company aims to improve the everyday lives of millions affected by these debilitating conditions.

Companion Spine

Series A in 2022
Companion Spine is a spine care company that specializes in interventional therapies and technologies aimed at addressing back pain effectively and with minimal disruption. The company focuses on providing diagnostic and medical implant products that facilitate the immediate and precise identification of spinal conditions and their underlying causes. By prioritizing patient safety and comfort, Companion Spine enables individuals to manage their pain while maintaining full spinal mobility, ultimately enhancing their quality of life.

Spine BioPharma

Series A in 2021
Spine BioPharma is focused on developing non-surgical therapies aimed at alleviating back pain and restoring functionality without relying on opioids. The company’s lead therapeutic candidate targets degenerative disc disease, offering potential benefits such as pain relief, functional restoration, and the slowing or prevention of disease progression. With a mission to enhance the quality of life for individuals suffering from degenerative spine conditions, Spine BioPharma seeks to deliver clinically proven, safe, and effective treatments that address pain and inflammation. Through its innovative pipeline, the company aims to improve the everyday lives of millions affected by these debilitating conditions.

Small Bone Innovations

Series F in 2010
Small Bone Innovations (SBi) is a medical device company specializing in the design, manufacture, and distribution of implants tailored for small bones and joints. Their product portfolio focuses on trauma and arthroplasty applications, catering specifically to the thumb, hand, wrist, elbow, foot, and ankle regions. SBi's offerings include basal joint arthritis treatments and implants designed to replace anatomic joint surfaces while preserving bones and minimizing disruption to collateral ligaments and soft tissues.

Small Bone Innovations

Series C in 2008
Small Bone Innovations (SBi) is a medical device company specializing in the design, manufacture, and distribution of implants tailored for small bones and joints. Their product portfolio focuses on trauma and arthroplasty applications, catering specifically to the thumb, hand, wrist, elbow, foot, and ankle regions. SBi's offerings include basal joint arthritis treatments and implants designed to replace anatomic joint surfaces while preserving bones and minimizing disruption to collateral ligaments and soft tissues.

Small Bone Innovations

Series B in 2005
Small Bone Innovations (SBi) is a medical device company specializing in the design, manufacture, and distribution of implants tailored for small bones and joints. Their product portfolio focuses on trauma and arthroplasty applications, catering specifically to the thumb, hand, wrist, elbow, foot, and ankle regions. SBi's offerings include basal joint arthritis treatments and implants designed to replace anatomic joint surfaces while preserving bones and minimizing disruption to collateral ligaments and soft tissues.

Spine Next

Series D in 2004
Spine Next is a France-based biotechnology company that specializes in the manufacture and marketing of orthopedic spinal implant devices intended for spinal fusion surgeries. Founded in 1999, the company has developed innovative products such as the Wallis system, a stabilization device designed to treat degenerative disc disease without the need for vertebral fusion. Spine Next was acquired by Abbott on October 25, 2004, enhancing its capabilities and market presence in the orthopedic medical device sector.

Raymedica

Venture Round in 2003
Raymedica, Inc. is a medical device manufacturer based in Minneapolis, Minnesota, focused on developing innovative solutions for the surgical treatment of low back pain, particularly in patients who have not found relief through conservative care. The company is dedicated to enhancing the technology created by its founder, Charles D. Ray, M.D. Raymedica's primary product is the PDN® prosthetic disc nucleus, designed to address low back pain due to degenerative disc disease. This device is surgically implanted into the evacuated nucleus disc space of the lumbar spine, where it aims to increase or maintain disc height, thereby restoring normal biomechanics and alleviating pain. Through its advancements in nucleus arthroplasty motion preservation technology, Raymedica seeks to improve the quality of life for patients worldwide suffering from disc-related issues.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.